Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome.

To compare the efficacy of statins and ɑ blockers drug therapies for benign prostatic hyperplasia (BPH) in patients with metabolic syndrome (MetS).

A total of three hundred patients were randomly distributed into three groups of one hundred patients each. Group 1 received only ɑ-adrenoceptor antagonist (ɑ-blocker, AB) (Tamsulosin), group 2 received only statin (atorvastatin), and group 3 received AB plus statin (Tamsulosin + Atorvastatin). The efficacy measurement was assessed by analyzing the changes from baseline in the total International Prostate Symptom Score (IPSS), disease-specific QoL question score and maximum urinary flow rate at the end of 6 months in each group and between the three groups.

Pre-treatment and post-treatment value of triglycerides (TG), high-density lipoprotein (HDL), and prostate volüme (PV) were not significantly different in AB group, while TG and PV were significantly lower in patients taking statin and combined therapy. The significant decrease was demonstrated in maximum urinary flow rate (Qmax) in three groups. However, the most significant decrease was observed in the combination therapy group. IPSS, postvoid residual urine volüme (PVR), and Quality of Life score (QoL) significantly changed in three groups.

We recommend of the use of statins in those men with BPH accompanied by MetS in which AB is ineffective alone.

The aging male : the official journal of the International Society for the Study of the Aging Male. 2018 Nov 21 [Epub ahead of print]

Suleyman Sami Cakir, Levent Ozcan, Emre Can Polat, Huseyin Besiroglu, Ramazan Kocaaslan, Alper Ötunctemur, Emin Ozbek

a Department of Urology , Okmeydani Training and Research Hospital , Istanbul , Turkey., b Department of Urology , Derince Training and Research Hospital , Kocaeli , Turkey., c Depatment of Urology , Catalca State Hospital , Istanbul , Turkey., d Department of Urology , Kafkas University School of Medicine , Kars , Turkey., e Department of Urology , Istanbul University, Cerrahpasa School of Medicine , Istanbul , Turkey.